Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Mitizax: Phase III data

Top-line data from the double-blind, European Phase III MERIT (MT-06) trial in 992 patients with house dust mite-induced allergic rhinitis showed that once-daily HDM AIT for 1 year

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE